NCT07292909 (EMPANTINFLAM) is a Phase 4 clinical trial of Empagliflozin (SGLT2i) in CAD - Coronary Artery Disease, sponsored by Hotel Dieu de France Hospital.

Who is sponsoring NCT07292909?

NCT07292909 is sponsored by Hotel Dieu de France Hospital.

What drugs are being tested in NCT07292909?

Interventions in NCT07292909: Empagliflozin (SGLT2i), Placebo.

What condition does NCT07292909 study?

NCT07292909 studies CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors.

Is NCT07292909 still recruiting?

NCT07292909 is currently recruiting now. Last updated 18 December 2025.

Last reviewed 2025-12-18 · How we verify

NCT07292909: EMPANTINFLAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Empagliflozin on Inflammation

Recruiting now Phase 4 Last updated 18 December 2025

What this trial tests

Phase 4 trial testing Empagliflozin (SGLT2i) in CAD - Coronary Artery Disease in 100 participants. Currently enrolling.

Timeline

1 September 2025

Primary endpoint
30 June 2027

30 September 2027

Quick facts

Lead sponsor	Hotel Dieu de France Hospital
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 September 2025
Primary completion	30 June 2027
Estimated completion	30 September 2027
Sites	1 location across Lebanon

Drugs / interventions tested

Empagliflozin (SGLT2i) (Empagliflozin (SGLT2i)) — full drug profile →
Placebo

Conditions studied

CAD - Coronary Artery Disease — all drugs for CAD - Coronary Artery Disease →
Inflamation — all drugs for Inflamation →
PCI — all drugs for PCI →
SGLT 2 Inhibitors — all drugs for SGLT 2 Inhibitors →

Sponsor

Hotel Dieu de France Hospital

Who can join

18 and older, any sex, with CAD - Coronary Artery Disease or Inflamation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood. He hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect. To document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure. Patients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Empagliflozin (SGLT2i)

Trials testing the same drug.

NCT05073692 — Comparison of Type 2 Diabetes Pharmacotherapy Regimens · completed

Other recruiting trials for CAD - Coronary Artery Disease

Currently open trials in the same condition.

NCT07451522 — Comparative Analysis of Analgesic Approaches in the Early Period After CABG · NA · recruiting
NCT07231835 — Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons · recruiting

Other Hotel Dieu de France Hospital trials

Trials by the same sponsor.

NCT06917768 — Oral Corticosteroids' Role in Pediatric Obstructive Sleep Apnea · NA · completed
NCT03578042 — Fixed-Free HTN Trial · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07292909 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hotel Dieu de France Hospital
Last refreshed: 18 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07292909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing